Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial
In RCT (n=611), once-weekly subcutaneous semaglutide produced significantly greater weight loss than placebo during 68 weeks (16.0% vs 5.7%, p < 0.001) in adults who are overweight or obese, when used as an adjunct to intensive behavioural therapy and initial low-calorie diet.
Source:
Journal of the American Medical Association